Added to YB: 2024-03-22
Pitch date: 2024-01-23
CSTL [bullish]
Castle Biosciences, Inc.
+66.34%
current return
Author Info
No bio for this author
Company Info
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma.
Market Cap
$1.1B
Pitch Price
$20.32
Price Target
N/A
Dividend
N/A
EV/EBITDA
-74.27
P/E
-56.02
EV/Sales
2.49
Sector
Health Care Providers and Services
Category
growth
Next Century Growth Investors SMID Cap Growth Strategy New Portfolio holding: Castle Biosciences, Inc.
CSTL: Diagnostics for skin/esophageal cancer & mental health. Skin tests still growing, acquisitions performing. Under-penetrated markets support growth outlook. Valuation compressed but strong balance sheet to fund expansion and target 2025 breakeven.
Read full article (1 min)